Aquestive Therapeutics, Inc. (AQST) Stock Price, News, Quote & History
This article provides a detailed overview of Aquestive Therapeutics, Inc. (AQST) stock, including its current price, historical data, key financial metrics, and company profile. It highlights the company's pharmaceutical products, proprietary pipeline, and performance against benchmarks like the S&P 500. The article also includes analyst insights and earnings trends.
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Aquestive Therapeutics has appointed Richard Daly to its Board of Directors, effective October 14, 2026. Daly brings over 30 years of leadership experience in the life sciences sector, including commercial and operating roles at major pharmaceutical and biotechnology companies. His expertise is expected to be invaluable as Aquestive prepares for the potential launch of Anaphylm, a treatment for severe allergic reactions.
Form 8K Aquestive Therapeutics Inc For: 29 September By Investing.com
This article announces that Aquestive Therapeutics Inc. filed a Form 8K on September 29th. The Form 8K is a crucial SEC filing used by public companies to announce major events that shareholders should know about. The article itself serves as a brief notification of this filing.
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced the appointment of Richard Daly to its Board of Directors, effective October 14, 2026. Mr. Daly brings over 30 years of leadership experience in the life sciences sector, including commercial and operating roles at major biopharmaceutical companies. His expertise is expected to be invaluable as Aquestive prepares for the potential launch of Anaphylm, a treatment for severe allergic reactions.
Aquestive appoints Rich Daly to board of directors
Aquestive Therapeutics, Inc. has announced the appointment of Rich Daly to its Board of Directors, effective October 14. Daly brings over 30 years of biopharmaceutical industry leadership experience, including senior roles at Angelini Pharma, Catalyst Pharmaceuticals, Takeda, and AstraZeneca. His appointment expands the board to eight directors as Aquestive prepares for the potential launch of Anaphylm.
Form 8K Aquestive Therapeutics Inc For: 29 September By Investing.com
This article reports that Aquestive Therapeutics Inc. filed a Form 8K on September 29. The brief news item from Investing.com indicates this filing as a significant event for the company, though no specific details about the content of the 8K are provided. The article also includes various market data and other news headlines.
Aquestive appoints Rich Daly to board of directors By Investing.com
Aquestive Therapeutics, Inc. has announced the appointment of Rich Daly to its Board of Directors, effective October 14th. Daly brings over 30 years of biopharmaceutical leadership experience, having held senior roles at companies like Angelini Pharma, Catalyst Pharmaceuticals, Takeda Pharmaceutical, and AstraZeneca. His appointment expands Aquestive's board to eight directors, with seven being independent, as the company prepares for the potential launch of its anaphylaxis treatment, Anaphylm.
Form 8K Aquestive Therapeutics Inc For: 29 September By Investing.com
This article from Investing.com reports that Aquestive Therapeutics Inc. filed a Form 8K on September 29. The filing is a standard disclosure for significant events that shareholders should know about. No specific details about the content of the 8K are provided within the article.
Aquestive Therapeutics elects Richard J. Daly to its Board as Class I director
Aquestive Therapeutics (AQST) has elected Richard J. Daly to its Board as a Class I director, effective October 14, 2026. Daly has been determined independent by the Board and will receive an initial award of 57,000 stock options. His appointment increases the board's size from seven to eight directors, with seven now being independent.
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Aquestive Therapeutics, Inc. has appointed Richard Daly, a seasoned life sciences executive, to its Board of Directors, effective October 14, 2026. Daly brings over 30 years of leadership experience from large pharmaceutical companies and emerging biotechnology firms, with a strong focus on commercial and operating roles. His appointment aims to bolster the company's commercial expertise as it prepares for the potential launch of Anaphylm, a treatment for severe allergic reactions.
Aquestive Therapeutics posts investor presentation; NDA resubmission for Anaphylm, $98.5M cash
Aquestive Therapeutics (AQST) has released an investor presentation, detailing the resubmission of its NDA for Anaphylm (dibutepinephrine) sublingual film to the FDA on September 17, 2026, with a request for expedited review. The company stated this resubmission addresses issues raised in a January 30, 2026 Complete Response Letter. Aquestive reported $98.5 million in cash and equivalents as of June 30, 2026, and projects Anaphylm to achieve over $1 billion in peak annual revenue, positioning it as the first non-device orally delivered epinephrine candidate if approved, with plans for ex-U.S. filings in Canada by year-end 2026 and in the EU in Q1 2027.
Anaphylm returns to FDA after Aquestive addresses usability, PK concerns
Aquestive Therapeutics has resubmitted its New Drug Application (NDA) for Anaphylm, a sublingual film for treating Type I allergic reactions, to the FDA. This resubmission addresses concerns raised in a previous Complete Response Letter regarding packaging usability and a confirmatory pharmacokinetic study, issues that Aquestive has now addressed with redesigned packaging and new study data. The FDA will determine the review timeline for the resubmission, with potential approval leading to competition with existing epinephrine treatments.
Allergy film that cuts dosing time resubmitted by Aquestive (NASDAQ: AQST)
Aquestive Therapeutics (NASDAQ: AQST) has resubmitted its New Drug Application (NDA) for Anaphylm, an allergy sublingual film, to the FDA. This resubmission addresses concerns raised in a previous Complete Response Letter, incorporating new human factors and pharmacokinetic data that demonstrate significant improvements in administration time. The company aims to target the substantial and growing anaphylaxis market in the U.S.
Aquestive Therapeutics (AQST) CEO sells 25,000 shares in preset plan trade
Aquestive Therapeutics (AQST) CEO Daniel Barber sold 25,000 shares of common stock on September 15, 2026, through an open-market transaction under a Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $4.8195, totaling approximately $120,488. Following this sale, Barber directly holds 652,317 shares of Aquestive Therapeutics common stock.
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm Sublingual Film
Aquestive Therapeutics has resubmitted its New Drug Application (NDA) to the FDA for Anaphylm (dibutepinephrine) sublingual film for treating Type I allergic reactions, including anaphylaxis. The resubmission follows a Complete Response Letter from the FDA and includes positive human factors and pharmacokinetic study results, particularly noting a reduced pouch-opening time. The company believes Anaphylm, a needle-free and highly portable treatment, could significantly improve the management of severe allergic reactions if approved.
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics has resubmitted its New Drug Application (NDA) to the FDA for Anaphylm™ (dibutepinephrine) sublingual film, a treatment for Type I allergic reactions including anaphylaxis. This resubmission follows a Complete Response Letter from the FDA and is supported by positive human factors and pharmacokinetic study results. The company anticipates the FDA will determine the classification and review timeline for the resubmission.
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics announced the resubmission of its New Drug Application (NDA) to the FDA for Anaphylm™ (dibutepinephrine) sublingual film, designed to treat Type I allergic reactions, including anaphylaxis. This resubmission addresses the FDA's Complete Response Letter by incorporating positive human factors and pharmacokinetic study results, leading to an improved packaging design and administration instructions. The company is optimistic about Anaphylm's potential to offer a rapid-acting, needle-free, and highly portable epinephrine treatment option, which could be a significant advancement for patients experiencing severe allergic reactions.
Aquestive Therapeutics CEO Barber sells $120,487 in shares
Daniel Barber, CEO of Aquestive Therapeutics, sold 25,000 shares of company stock for a total of $120,487 on September 15, 2026. Following this transaction, Barber still directly holds 652,317 shares. The company, with a market cap of $602 million, is currently unprofitable but is considered undervalued by InvestingPro analysis, and recently reported a 38% increase in revenue.
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) on behalf of investors who suffered losses between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive Therapeutics made materially false and misleading statements regarding the approval timeline for its Anaphylm sublingual film, failing to disclose significant human factors issues. Investors who wish to lead the lawsuit must come forward by May 4, 2026.
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced its participation in four investor conferences in September 2026, including the Wells Fargo Healthcare Conference, Cantor Healthcare Conference, Citi's 2026 Biopharma Back to School Summit, and H.C. Wainwright 27th Annual Global Investor Conference. The company will host investor meetings and present at some of these events, with webcasts available for certain presentations. Aquestive Therapeutics is a pharmaceutical company focused on advancing medicines through innovative science and delivery technologies, including its proprietary Anaphylm™ and AQST-108 platforms.
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Aquestive Therapeutics, Inc. announced its participation in four investor conferences in September 2026, including the Wells Fargo Healthcare Conference, Cantor Healthcare Conference, Citi’s Biopharma Back to School Summit, and H.C. Wainwright Global Investor Conference. The company will host investor meetings and give presentations, with webcasts available for some events. Aquestive Therapeutics is a pharmaceutical company focused on advancing medicines through innovative science and delivery technologies, including its proprietary products and CDMO services.
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Aquestive Therapeutics, Inc. announced its participation in four investor conferences in September 2026, including the Wells Fargo Healthcare Conference, Cantor Healthcare Conference, Citi’s Biopharma Back to School Summit, and H.C. Wainwright 27th Annual Global Investor Conference. Management will be available for investor meetings, and webcasts of certain events will be available online. The company is advancing medicines such as Anaphylm™ and AQST-108, leveraging its expertise in oral film delivery technologies.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) for corporate wrongdoing. The firm encourages shareholders who purchased Aquestive securities prior to June 16, 2025, and still hold them, to connect to assist the investigation. The investigation aims to restore investor capital and ensure corporate accountability.
Blue Owl Capital Holdings LP Makes New $3.92 Million Investment in Aquestive Therapeutics, Inc. $AQST
Blue Owl Capital Holdings LP has acquired a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST), purchasing 942,932 shares worth approximately $3.92 million, representing 0.75% of the company. Other institutional investors also increased their holdings, bringing total institutional ownership to 32.45%. Despite a recent quarterly loss that missed consensus estimates, analysts maintain a "Buy" rating for Aquestive Therapeutics, with an average target price of $8.50.
Aquestive Therapeutics Earnings Call Highlights Anaphylm Progress
Aquestive Therapeutics reported strong Q2 2026 results, with total revenue up 38% and a narrowed adjusted EBITDA loss, demonstrating improving financial trends. The company highlighted significant progress on its Anaphylm epinephrine film, including successful human factors and pharmacokinetic studies, and is on track for NDA resubmission in Q3. While acknowledging near-term risks regarding FDA timing and payer adoption, Aquestive is preparing for a focused launch, supported by a substantial cash balance and a new debt facility.
Latash Investments LLC Acquires New Holdings in Aquestive Therapeutics, Inc. $AQST
Latash Investments LLC has acquired a new stake in Aquestive Therapeutics (NASDAQ:AQST), purchasing 243,134 shares valued at $1.01 million in the second quarter, making it their 7th largest position. Despite missing earnings per share estimates, Aquestive Therapeutics exceeded revenue expectations, and its stock price rose by 6.2% to $4.59. Analyst sentiment remains largely positive with a "Buy" consensus and an $8.50 average price target, although there has been a recent insider sale and some "sell" ratings.
Aquestive Therapeutics (NASDAQ:AQST) Sees Strong Trading Volume - Time to Buy?
Aquestive Therapeutics (NASDAQ:AQST) experienced a significant surge in trading volume, with shares rising 8.2% to $4.595. While analyst sentiment is generally positive with an average "Buy" rating and an $8.50 price target, the company recently missed earnings expectations despite exceeding revenue. Institutional ownership is at 32.45%, but a director recently sold 25,000 shares.
Aquestive Therapeutics CEO Daniel Barber Sells 25,000 Shares Under Rule 10b5-1 Plan
Daniel Barber, President and CEO of Aquestive Therapeutics, Inc. (NASDAQ: AQST), sold 25,000 shares of the company's common stock on August 17, 2026, at a weighted average price of $4.2867 per share. This transaction was conducted under a pre-established Rule 10b5-1 plan, and following the sale, Barber beneficially holds 585,574 shares of common stock. The details were disclosed in a Form 4 filing with the SEC on August 19, 2026.
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) for alleged corporate wrongdoing. The firm is encouraging stockholders who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with the investigation. The firm represents investors in class actions on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Aquestive (NASDAQ: AQST) CCO's 2,714-share tax withholding detailed
Aquestive Therapeutics' Chief Commercial Officer, Sherry Korczynski, had 2,714 shares of company common stock withheld to cover tax obligations stemming from the vesting of Restricted Stock Units. The shares were valued at $4.25 each. Following this transaction, Korczynski directly holds 235,689 shares of Aquestive Therapeutics common stock.
Aquestive (NASDAQ: AQST) CEO sells 25K shares under preset plan
Aquestive Therapeutics, Inc. (AQST) CEO Daniel Barber sold 25,000 shares of common stock on August 17, 2026, under a Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $4.2867, ranging from $4.24 to $4.35 per share. Following this transaction, Mr. Barber directly holds 585,574 shares of the company's common stock.
Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST
Walleye Capital LLC has acquired a new stake of 282,568 shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST), valued at approximately $1.18 million. Institutional investors collectively hold 32.45% of the company's stock, while insider ownership stands at 6.81%. Despite a wider-than-expected quarterly loss, analysts maintain a broadly positive "Buy" rating with a consensus price target of $8.50.
Aquestive Therapeutics (NASDAQ:AQST) Lowered to "Sell" Rating by Wall Street Zen
Aquestive Therapeutics (NASDAQ:AQST) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen analysts. The company reported a Q2 earnings per share miss of ($0.18) against an estimated ($0.10), although revenue of $13.82 million exceeded the $11.42 million consensus. Despite the downgrade, other analysts maintain a consensus "Buy" rating with an average price target of $8.50 for AQST.
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ (dibutepinephrine) sublingual film, supporting its planned NDA resubmission to the FDA in Q3 2026. The studies showed significant improvements in packaging usability and film administration, addressing previous FDA concerns. Self-administration PK results were comparable to clinician-administered results, and even incorrect film placement yielded clinically meaningful pharmacodynamic responses, bolstering confidence in Anaphylm as a potential non-invasive epinephrine product.
Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission
Aquestive Therapeutics (AQST) stock saw a 4% dip despite reporting improved Q2 2026 financials, with a narrowed net loss and US$98.5m in cash. The company is nearing resubmission of its Anaphylm New Drug Application to the FDA, having addressed all Complete Response Letter requests, aiming to pivot epinephrine treatment towards a needle-free oral film. However, concerns persist regarding ongoing adjusted EBITDA losses, cash burn, and the lack of an FDA acceptance letter or review clock for Anaphylm, which continue to fuel a bearish sentiment on the stock.
LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
LifeSci Capital analyst Francois Brisebois has reaffirmed a Buy rating for Aquestive Therapeutics (AQST.US), maintaining a target price of $10. According to TipRanks data, Brisebois has a 43.0% success rate and a 6.3% average return over the past year. This report highlights the analyst's consistent positive outlook on the pharmaceutical company.
Wasatch Advisors LP Has $5.76 Million Position in Aquestive Therapeutics, Inc. $AQST
Wasatch Advisors LP significantly increased its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 57.8% in Q2, bringing its total holding to 1.39 million shares valued at $5.76 million. Despite institutional investors collectively owning 32.45% of the company and a "Buy" consensus rating from analysts, Aquestive reported a wider-than-expected Q2 loss and issued full-year revenue guidance below consensus.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts
Aquestive Therapeutics (NASDAQ:AQST) has received an average "Buy" rating from analysts, with a consensus 12-month price target of $8.50. Despite exceeding second-quarter revenue expectations, the company reported a larger-than-expected loss per share and issued full-year revenue guidance below analyst consensus. Insider selling and institutional trading activity were also noted in the report.
Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission
Aquestive Therapeutics (AQST) stock experienced a 4% dip despite positive Q2 results showing increased liquidity and reaffirmed revenue guidance. The company is nearing resubmission of its Anaphylm New Drug Application, with management addressing FDA concerns. However, ongoing adjusted EBITDA losses and the dependence on a single late-stage asset raise concerns about cash burn and financing risks for investors.
Aquestive Therapeutics Releases Q2 2026 Financial Results
Aquestive Therapeutics (AQST) reported a Q2 2026 diluted loss per share of $0.18, exceeding the expected loss of $0.11, with total revenue reaching $13.8 million, a 38.0% increase year-over-year. The company's net loss for the quarter was $22.9 million, and it ended with $98.5 million in cash and cash equivalents. Aquestive Therapeutics set its full-year revenue guidance between $46.0 million and $50.0 million.
Aquestive Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AQST) 2026-08-12
Aquestive Therapeutics, Inc. (AQST) published its Q2 2026 earnings call presentation on August 12, 2026. The company reported an EPS of -$0.07, beating estimates by $0.05, and revenue of $13.82 million, a 38.15% year-over-year increase, beating estimates by $2.26 million. This presentation provides details discussed during their earnings call.
Earnings call transcript: Aquestive Therapeutics tops revenue views in Q2 2026
Aquestive Therapeutics reported Q2 2026 revenue of $13.82 million, exceeding analyst estimates, but also posted a wider-than-expected loss of $0.18 per share due to an $11.7 million debt extinguishment charge. The company remains on track to resubmit its Anaphylm NDA to the FDA in Q3 2026, supported by positive human factors and pharmacokinetic study results, and is preparing for a potential launch focusing on allergists. Aquestive maintained its full-year 2026 revenue guidance of $46 million to $50 million.
Aquestive Therapeutics Q2 Loss Widens, Revenue Rises
Aquestive Therapeutics reported a wider net loss in Q2 compared to the previous year, despite an increase in total revenue. The company also updated its full-year 2026 outlook, anticipating total revenue to be between $58 million and $62 million, with non-GAAP adjusted EBITDA expected to range from -$40 million to -$35 million.
Aquestive Therapeutics: Q2 Earnings Snapshot
This article provides a brief "Q2 Earnings Snapshot" for Aquestive Therapeutics. It is a very short piece, indicating that the company's Q2 earnings were reported.
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics announced its Q2 2026 financial results, highlighting progress with Anaphylm™ (dibutepinephrine) sublingual film, including successful completion of human factors and pharmacokinetic studies. The company remains on track to resubmit the Anaphylm NDA to the FDA in Q3 2026 and plans ex-U.S. filings. Total revenues increased to $13.8 million, up 38% year-over-year, while the net loss was $22.9 million, partly due to a one-time debt extinguishment loss.
Aquestive Plans to Take Epi Film Back to FDA with Positive Data
Aquestive Therapeutics plans to resubmit its drug application for Anaphylm, an oral dissolving film for severe allergic reactions, to the FDA this fall. This follows the completion of two additional studies requested by the FDA, which have yielded positive results regarding revised packaging, ease of use, and epinephrine absorption. The company is confident in its new data and aims for expedited review, with plans to seek approval in Canada, Europe, and the UK in late 2026.
Aquestive Therapeutics (NASDAQ:AQST) Shares Up 7.1% - Here's Why
Aquestive Therapeutics (NASDAQ:AQST) saw its shares rise 7.1% to $4.595, with a market capitalization of approximately $574 million. The company's stock holds a consensus "Buy" rating from analysts with an average price target of $8.50, driven by its recent beat on quarterly earnings expectations. Despite positive analyst sentiment and strong earnings, company insiders have recently sold shares under pre-arranged trading plans.
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ sublingual film, an epinephrine product for severe allergic reactions. These results support the planned resubmission of its New Drug Application (NDA) to the FDA in the third quarter of 2026, addressing previous concerns regarding packaging and administration. The studies demonstrated significant improvements in ease of use and effective drug delivery, even with some incorrect placements.
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study
Aquestive Therapeutics (AQST) announced positive results from human factors and pharmacokinetic validation studies for its Anaphylm sublingual film, a severe allergy treatment. These studies address prior FDA feedback, demonstrating significant improvements in product usability and effective drug delivery even with slight misplacement. The company plans to resubmit its New Drug Application to the FDA in Q3 2026 and is pursuing regulatory approvals in other regions.
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film
Aquestive Therapeutics has announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ (dibutepinephrine) sublingual film. These results support the planned resubmission of its New Drug Application (NDA) to the FDA in Q3 2026, addressing previous issues with packaging and administration. The company believes Anaphylm has the potential to be the first non-invasive, orally delivered epinephrine product for severe allergic reactions.
